Individualizing Therapy in the Management of
Relapsing Multiple Sclerosis: Expert Strategies
for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Celgene and Sanofi Genzyme

Multiple Sclerosis (MS) is a chronic progressive disease and is the most common neurological cause of disability among young adults in the United States with a prevalence of approximately 400,000 cases. Multiple sclerosis may not be diagnosed for months to years after the onset of symptoms and some strategies for diagnosis include a careful medical history, a neurologic exam and various tests, including magnetic resonance imaging (MRI), evoked potentials (EP) and spinal fluid analysis. Although there is no cure for MS, many advances in treatment options have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Treatment is focused on disease-modifying agents, which helps lessen the frequency and severity of relapses, reduce lesions in the brain, and help slow or stop disability. Many therapeutic and technological advances are improving our understanding of the complex mechanisms involved in multiple sclerosis (MS) immunopathophysiology. Several investigational agents that have recently completed clinical trials that focus on Sphingosine-1-phosphate (S1P) signaling. S1P-based therapeutics in current clinical trials have shown improved efficacy, safety and deliverability.

Upon completion of this activity, participants will be able to:

  • Examine the mechanisms of action, efficacy, and safety profiles of current and emerging relapsing multiple sclerosis (MS) therapies and their effect on staging and sequencing

  • Review evidence-based data for the rationale of sequencing, switching, and/or escalating MS therapeutics

  • Assess the individualized factors involved when establishing MS therapeutic strategies including patient, disease, and treatment characteristics that factor into MS treatment selection and considerations for predicting treatment response and identifying when to switch therapies

  • Analyze the most recent clinical trial data of S1P therapeutics for the management of patients with relapsing multiple sclerosis

  • Analyze guideline updates on the role of MRI in evaluating prognosis, disease progression and therapeutic decision-making for improved relapsing MS patient outcomes

  • Implement value-based approaches that will balance costs with improved outcomes in relapsing MS management

Faculty: Lily Jung Henson, MD
Chief of Neurology
Piedmont Healthcare


Dr. Henson owns stock in Merck. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Celgene and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue